Summary of share price highs, lows and changes for Circio Holding
Historical stock prices
Current Share Price	NOK 0.76
52 Week High	NOK 1.33
52 Week Low	NOK 0.039
Beta	-1.22
1 Month Change	70.50%
3 Month Change	787.46%
1 Year Change	1,464.08%
3 Year Change	-36.92%
5 Year Change	-96.80%
Change since IPO	-96.97%

Recent updates

Shareholder Returns

	TA50	DE Biotechs	DE Market
7D	2.9%	-0.2%	0.3%
1Y	1,464.1%	-2.7%	6.0%

Return vs Industry: TA50 exceeded the German Biotechs industry which returned -2.7% over the past year.

Return vs Market: TA50 exceeded the German Market which returned 6% over the past year.

Price Volatility

Is TA50's price volatile compared to industry and market?
TA50 volatility
TA50 Average Weekly Movement	31.6%
Biotechs Industry Average Movement	9.2%
Market Average Movement	6.0%
10% most volatile stocks in DE Market	13.6%
10% least volatile stocks in DE Market	2.6%

Stable Share Price: TA50's share price has been volatile over the past 3 months compared to the German market.

Volatility Over Time: TA50's weekly volatility (32%) has been stable over the past year, but is still higher than 75% of German stocks.

About the Company

Founded	Employees	CEO	Website
2010	9	Erik Wiklund	www.circio.com

Circio Holding ASA, a biotechnology company, develops novel circular RNA and immunotherapy medicines. The company is developing TG01, a cancer vaccine targeting driver mutations, which is in three clinical trials for multiple myeloma, and pancreatic and lung cancer; and circVec circRNA vector platform, a modular genetic cassette for biogenesis of multifunctional circRNAs in human cells. It has a collaboration with Certest Biotec, S.L. for formulation of circVec.

Circio Holding ASA Fundamentals Summary

How do Circio Holding's earnings and revenue compare to its market cap?
TA50 fundamental statistics
Market cap	€182.57m
Earnings (TTM)	-€4.22m
Revenue (TTM)	n/a

0.0x

P/S Ratio

-43.3x

P/E Ratio

Is TA50 overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
TA50 income statement (TTM)
Revenue	NOK 0
Cost of Revenue	NOK 0
Gross Profit	NOK 0
Other Expenses	NOK 45.91m
Earnings	-NOK 45.91m

Last Reported Earnings

Dec 31, 2025

Next Earnings Date

Aug 31, 2026

Earnings per share (EPS)	-0.19
Gross Margin	0.00%
Net Profit Margin	0.00%
Debt/Equity Ratio	-67.0%

How did TA50 perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2026/04/23 16:55
End of Day Share Price	2026/04/22 00:00
Earnings	2025/12/31
Annual Earnings	2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Circio Holding ASA is covered by 3 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Arvid Necander	Carnegie Investment Bank AB
Geir Holom	DNB Carnegie
Jonas Peciulis	Edison Investment Research

Circio Holding (TA50) Stock Overview

Risk Analysis

The Market Is Sleeping on This Parkinson's Biotech - And I Think That's a Mistake

Circio Holding ASA Competitors

Dextech Medical

Darwin

Hamlet BioPharma

Formycon

Price History & Performance

Recent News & Updates

Circio Holding ASA has filed a Follow-on Equity Offering in the amount of NOK 82.49999 million.

Circio Holding ASA to Report First Half, 2026 Results on Aug 31, 2026

Circio Holding ASA has completed a Follow-on Equity Offering in the amount of NOK 50 million.

Circio Holding ASA has filed a Follow-on Equity Offering in the amount of NOK 50 million.

Circio Holding ASA to Report Fiscal Year 2024 Final Results on Apr 10, 2025

Now 98% undervalued after recent price drop

Recent updates

Circio Holding ASA has filed a Follow-on Equity Offering in the amount of NOK 82.49999 million.

Circio Holding ASA to Report First Half, 2026 Results on Aug 31, 2026

Circio Holding ASA has completed a Follow-on Equity Offering in the amount of NOK 50 million.

Circio Holding ASA has filed a Follow-on Equity Offering in the amount of NOK 50 million.

Circio Holding ASA to Report Fiscal Year 2024 Final Results on Apr 10, 2025

Now 98% undervalued after recent price drop

Circio Holding ASA Presents Circvec Circular RNA in Vivo Expression Proof-Of-Concept Data At ESGCT 2024 Annual Meeting

New major risk - Revenue and earnings growth

New major risk - Financial position

Circio Announces Strengthened in Vivo Data and Enhanced Circvec 2.2 Design

New major risk - Shareholder dilution

Circio Holding ASA has filed a Follow-on Equity Offering in the amount of NOK 60 million.

Circio Announces in Vivo Proof-Of-Concept for Its circVec circular RNA Platform Technology and Reinforced Gene Therapy Focus

Forecast breakeven date pushed back to 2026

New minor risk - Financial data availability

Circio Holding ASA Announces Dosing of First Patient in the Collaborative Phase 2 Trial Sponsored by Georgetown University

Circio Holding ASA, Annual General Meeting, Jun 05, 2024

IOVaxis Therapeutics Files Updated TG01 Investigational New Drug Application with the Chinese National Medical Products Administration

Circio Holding ASA Announces Completion of Planned Safety Review and Opening for Full Enrollment of TG01 Study At Oslo University Hospital

New major risk - Financial position

Forecast to breakeven in 2024

Forecast to breakeven in 2024

Targovax Announces That the TG01 Study in Multiple Myeloma At Oslo University Hospital Has Received Regulatory Approvals to Proceed

Targovax ASA to Report Q4, 2023 Results on Feb 15, 2024

High number of new directors

Targovax ASA Completes ONCOS-102 Phase 1b Study in PD-1 CPI Resistant Advanced Melanoma Has Been Published in the Oncology Journal Clinical Cancer Research

Targovax ASA Receives Approval to Proceed with the Oncos-102 Phase 2 Melanoma Study from the US FDA

Forecast to breakeven in 2024

Targovax ASA Announces that the FDA Grant Authorization to Initiate Clinical Trials with the Enhanced TG01 RAS Vaccine in the USA

High number of new directors

Targovax ASA Announces Board Changes

Forecast to breakeven in 2024

Targovax ASA Appoints Lubor Gaal as Chief Financial Officer, Effective March 7, 2022

Forecast to breakeven in 2024

Targovax ASA Announces ONCOS-102 Achieves 25.0 Months Median Overall Survival in First Line Mesothelioma

Chief Financial Officer Torbjørn Furuseth has left the company

Targovax Receives Fast Track Designation for Oncos-102 in Melanoma

Targovax Announces Completed Enrollment in the Phase 1/2 Trial with ONCOS-102 in Combination with Durvalumab in Patients with Advanced Colorectal Cancer with Peritoneal Malignancies

Targovax ASA's ONCOS-102 Mesothelioma 24-Month Data Shows Class-Leading Median Overall Survival

Targovax ASA Announces Board Changes

Targovax Granted US Patent for Oncos-102 in Combination with Checkpoint Inhibitors

Continued Survival Benefit in Targovax's ONCOS-102 Trial in Mesothelioma At the 21-Month Follow-Up

Revenue misses expectations

Targovax ASA Receives Fast-Track Designation for ONCOS-102

Targovax ASA and Papyrus Therapeutics Enter Research Collaboration to Develop Novel ONCOS Viruses with Receptor Tyrosine Kinase (RTK) Inhibitor Functionality

Targovax grants IOVaxis 3 months extension to the exclusive license option for TG mutant RAS vaccines in Greater China and Singapore

New 90-day high: €1.02

New 90-day high: €0.86

Targovax ASA Demonstrates Encouraging Survival Data for Oncos-102 in Mesothelioma

Revenue in line with expectations

Targovax ASA to Report Q1, 2021 Final Results on May 06, 2021

Targovax Announces Formation of New Scientific Advisory Board

New 90-day low: €0.57

Targovax ASA has completed a Follow-on Equity Offering in the amount of NOK 75.000003 million.

Targovax ASA Announces ONCOS-102 and Durvalumab Trial Successfully Completes Part 1 in Colorectal Cancer

New 90-day high: €0.72

Shareholder Returns

Price Volatility

About the Company

Circio Holding ASA Fundamentals Summary

Earnings & Revenue

Company Analysis and Financial Data Status

Data Sources